Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.

Ziegler AG, Achenbach P, Weiß A, Berner R, Casteels K, Elding Larsson H, Haupt F, Hommel A, Jacobs A, Kordonouri O, Lundgren M, Ołtarzewski M, Pfirrmann M, Snape MD, Szypowska A, Todd JA, Vatish M, von dem Berge T, Winkler C, Bonifacio E, GPPAD-POInT Study Group

Open source

DOI: 10.1016/s0140-6736(25)01726-x
Published: 2025 Nov 29
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-25-01726-x,
  title = {Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.},
  author = {Ziegler AG and Achenbach P and Weiß A and Berner R and Casteels K and Elding Larsson H and Haupt F and Hommel A and Jacobs A and Kordonouri O and Lundgren M and Ołtarzewski M and Pfirrmann M and Snape MD and Szypowska A and Todd JA and Vatish M and von dem Berge T and Winkler C and Bonifacio E and GPPAD-POInT Study Group},
  year = {2025},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(25)01726-x},
  url = {https://doi.org/10.1016/s0140-6736(25)01726-x}
}

RIS

TY  - JOUR
TI  - Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
AU  - Ziegler AG
AU  - Achenbach P
AU  - Weiß A
AU  - Berner R
AU  - Casteels K
AU  - Elding Larsson H
AU  - Haupt F
AU  - Hommel A
AU  - Jacobs A
AU  - Kordonouri O
AU  - Lundgren M
AU  - Ołtarzewski M
AU  - Pfirrmann M
AU  - Snape MD
AU  - Szypowska A
AU  - Todd JA
AU  - Vatish M
AU  - von dem Berge T
AU  - Winkler C
AU  - Bonifacio E
AU  - GPPAD-POInT Study Group
PY  - 2025
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(25)01726-x
UR  - https://doi.org/10.1016/s0140-6736(25)01726-x
ER  -

APA

AG, Z., P, A., A, W., R, B., K, C., H, E. L., F, H., A, H., A, J., O, K., M, L., M, O., M, P., MD, S., A, S., JA, T., M, V., T, V. D. B., C, W., E, B., & Group, G. S. (2025). Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(25)01726-x

Source records

pubmed · retrieved 2026-09-26T00:17:04.450Z